Solid Tumor Clinical Trials in The Bronx, New York
5 studies are recruiting for solid tumor in The Bronx, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
Studies now recruiting
-
Psychotherapy Intervention for Latinos With Advanced Cancer
The purpose of this study is to adapt a counseling intervention called Meaning Centered Psychotherapy to make it culturally relevant for Latinos. Cancer affects patients and their loved ones. Latinos often experience greater challenges due to the cancer. However, few studies and interventions focus…
- Stage
- Not phased
- Ages
- 18 and older
- Site
- Lincoln Medical and Mental Health Center, The Bronx, New York
- Locations
- 4 in total
- Run by
- Memorial Sloan Kettering Cancer Center
-
Psychotherapy Intervention for Latinos With Adv Cancer
The purpose of this study is to adapt a counseling intervention called Meaning Centered Psychotherapy to make it culturally relevant for Latinos. Cancer affects patients and their loved ones. Latinos often experience greater challenges due to the cancer. However, few studies and interventions focus…
- Stage
- Not phased
- Ages
- 18 and older
- Site
- Lincoln Medical and Mental Health Center, The Bronx, New York
- Locations
- 4 in total
- Run by
- Memorial Sloan Kettering Cancer Center
-
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
This is a first-in-human Phase I/II, open-label, multicenter, dose-escalation and expansion study designed to evaluate the safety, pharmacokinetics, and preliminary activity of GDC-7035 as a single agent and in combination with other anti-cancer therapies in participants with advanced or metastatic…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Montefiore Einstein Cancer Center, The Bronx, New York
- Locations
- 42 in total
- Run by
- Genentech, Inc.
-
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizuma…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Montefiore Medical Center, The Bronx, New York
- Locations
- 42 in total
- Run by
- Inhibrx Biosciences, Inc
-
Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values
The purpose of this study is to translate and tailor for Latinx participants a program called Communicating with Oncology Nurses about Values from the Outset (CONVO). In CONVO, routine cancer care for each participant includes a discussion between the nurse and participant about the participant's h…
- Stage
- Not phased
- Ages
- 21 and older
- Site
- SBH Health System, The Bronx, New York
- Locations
- 5 in total
- Run by
- Memorial Sloan Kettering Cancer Center
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.